ACCESS Newswire

Cannabis Suisse Corp

15.7.2021 14:02:27 CEST | ACCESS Newswire | Press release

Share
Cannabis Suisse Corp. Announces the Results of Laboratory Testing of Its New Product Line and Creation the "LEARN" Section on the Website

DIETIKON, SWITZERLAND / ACCESSWIRE / July 15, 2021 / Cannabis Suisse Corp. (OTC PINK:CSUI), a Nevada incorporated distribution company for recreational cannabis products and CBD oils, announces the results of laboratory testing of its new product line created for the upcoming launch on Shopify.

This news follows a recent announcement on the decision to choose ACS Laboratory as a CBD laboratory for testing the first shipment of the new Swiss4Life CBD brand, created for the launch of an online store on Shopify platform. The samples of products were sent to ACS laboratory to obtain СOA proving the quality of the new brand name CBD oils to the potential customers.

The certificates are ready for all the six types of current products: THC Free CBD Oil (Cherry Vanilla and Creme de Menthe) and CBD Tinctures with different therapeutic effects.

THC Free CBD Oil 1500 mg Cherry Vanilla has 1,521.586mg of Cannabinoids total (5.376%). 5.096% (1,442.211mg) are represented by CBD, 0.131% (36.992mg) are CBG, 0.051% (14.474mg) are CBN. The number of other Cannabinoids is 0.099% (27.909mg). THC is not detected.

THC Free CBD Oil 2500 mg Creme de Menthe contains 2,458.295mg of Cannabinoids total (8.654%). 8.177% (2,322.842mg) are represented by CBD, 0.209% (59.457mg) are CBG, 0.098% (27.851mg) are CBN. The number of other Cannabinoids is 0.169% (48.145mg). THC is not detected.

THC Free CBD Oil 3500 mg Cherry Vanilla has 3,513.119mg of Cannabinoids total (12.299%). 11.770% (3,362.096mg) are represented by CBD, 0.275% (78.554mg) are CBG, 0.115% (32.821mg) are CBN. The number of other Cannabinoids is 0.139% (39.648mg). THC is not detected.

CBD TINCTURES Anti-Inflammatory/Pain Relief/Focus contains 934.326mg of Cannabinoids total (3.328%). 3.314% (930.404mg) are represented by CBD, THC is not detected.

CBD TINCTURES Anti-Inflammatory/Pain Relief/Anti-Stress Formula has 920.788mg of Cannabinoids total (3.652%). 3.632% (915.728mg) are represented by CBD, THC is not detected.

CBD TINCTURES Natural Sleep Formula contains 913.149mg of Cannabinoids total (3.331%). 3.331% (913.149mg) are represented by CBD, other Cannabinoids or THC are not detected.

Since the Company received the certificates of analysis, a special page has been created on the site in the "LEARN" section so that users can see them at any time on their own and make sure of their authenticity. The COA were uploaded there along with the testing date.

ABOUT CANNABIS SUISSE CORP.

Cannabis Suisse Corp. is a public US Company incorporated in Nevada state. The Company operates in the field of distribution of recreational cannabis products and CBD oils. Cannabis Suisse Corp. currently sells via a distribution network of retailers and online shops, under the retail brand Swiss4Life. Swiss4Life products are made of USA hemp only and contain no THC, GMO or Gluten. They have not been evaluated by the FDA and are not designated for medical use. However, all the products available are manufactured by FDA Registered Entities and tested by independent third-party laboratories. Cannabis Suisse Corp's products are laboratory tested to ensure the end-users have access to a standardized, safe, and consistent product.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that

are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties, and other factors, which may cause the actual results, performance, or achievements of Cannabis Suisse Corp. to be materially different from the statements made herein.

CONTACT:

Alain Parrik
Cannabis Suisse Corp.
+41445865314
alain.parrik@cannabissuisse.biz

SOURCE: Cannabis Suisse Corp.



View source version on accesswire.com:
https://www.accesswire.com/655563/Cannabis-Suisse-Corp-Announces-the-Results-of-Laboratory-Testing-of-Its-New-Product-Line-and-Creation-the-LEARN-Section-on-the-Website

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

QorusDocs Named LegalTech AI Platform of the Year and Ranked No. 1 Proposal Management Software17.11.2026 15:00:00 CET | Press release

BELLEVUE, WA / ACCESS Newswire / November 17, 2026 / QorusDocs, the pursuit intelligence platform trusted by dozens of Am Law 200 and Global 200 law firms, today announced it has been named LegalTech AI Platform of the Year in the seventh annual LegalTech Breakthrough Awards program and ranked the No. 1 proposal management solution by Info-Tech Research Group's SoftwareReviews, based on verified end-user reviews. The recognitions cap a year of rapid growth in legal for QorusDocs, which forecasts it will double its annual recurring revenue (ARR) from law firms in the next 12 months by adding more high-profile firms to its list of big law customers, which already includes DLA Piper, Baker McKenzie, Herbert Smith Freehills Kramer and Womble Bond Dickinson. Firms are moving AI beyond research and drafting and into business development, where a winning pitch depends on the best representative matters, strong attorney biographies and winning pitch strategies: knowledge general AI tools lack.

Freezz Italia Awarded ESA Contract for IRIS(2) Low-LEO Pre-Operational and De-Risk Activities17.11.2026 14:00:00 CET | Press release

CORTONA, IT / ACCESS Newswire / November 17, 2026 / Freezz Italia has been awarded a contract by the European Space Agency (ESA), as prime contractor leading a European industrial consortium, for the Consolidation Phase of the IRIS² Low-LEO Pre-Operational and De-Risk Activities, part of the ESA Programme Related to EU Secure Connectivity. The activity will further mature Friisat, Freezz's satellite system architecture conceived specifically for operation in Very Low Earth Orbit (VLEO) and designed for future broadband Direct-to-Device (D2D) connectivity within the 3GPP 5G/6G Non-Terrestrial Network (NTN) framework. Under this ESA contract, Freezz Italia will consolidate the mission and system architecture, adapting Friisat's existing commercial design to meet the requirements of an IRIS²-compatible solution, including future governmental broadband Direct-To-Device secure-connectivity services. The work will address the system and service concepts, architecture and interfaces, security

International Business Times UK Increases Programmatic Revenue by 30% with Opti Digital17.11.2026 11:00:00 CET | Press release

PARIS, FR / ACCESS Newswire / November 17, 2026 / Opti Digital, the leading AdTech company specialising in publisher revenue optimisation, today announced the results of its collaboration with International Business Times UK, an international digital news brand delivering business, markets, technology and current affairs coverage to a global readership. Operating in a fast-moving news environment, International Business Times UK continuously explores opportunities to increase the value of its digital audience while maintaining control over advertising quality and user experience. The publisher identified an opportunity to generate incremental revenue from its existing audience and inventory through a monetisation experience that could be tested progressively and scaled across a broader share of its inventory. "We were looking for ways to generate more value from our existing inventory, and the performance quickly demonstrated the potential of the new experience. It has become a meaning

OBI Pharma Signs Collaboration and License Agreement with Novartis16.11.2026 09:10:00 CET | Press release

TAIPEI, TW / ACCESS Newswire / November 16, 2026 / OBI Pharma, Inc. (4174.TWO) ("OBI") announced that it has entered into a Collaboration and License agreement with Novartis Pharma AG ("Novartis") to develop next generation Antibody-Drug-Conjugates (ADCs) with novel payloads, using OBI's suite of platform technologies. Under the terms of the agreement, Novartis will receive worldwide rights to OBI's related patents and know-how using its ADC platform technologies on an exclusive basis for selected, undisclosed Novartis payload classes. In parallel, under the collaboration OBI will evaluate novellinker approaches with the Novartis payloads. Novartis will further have the option to expand the agreement to include additional novel payload classes. This agreement marks an important milestone for OBI and underscores the value of its differentiated ADC technology platform. The agreement recognizes the potential of OBI's proprietary technologies, including GlycOBI®, EndoSymeOBI®, HYPrOBI®, an

Digi Power X Reports Q3 2026 Revenue Up 85% and AI Revenue Up Over 400% Compared to Q213.11.2026 13:30:00 CET | Press release

MIAMI, FL / ACCESS Newswire / November 13, 2026 / Digi Power X Inc. (Nasdaq:DGXX)(Cboe Canada:DGX) ("Digi Power X" or the "Company"), an AI data center infrastructure operator, today reported its financial and operating results for the third quarter ended September 30, 2026 (all amounts in U.S. dollars, unless otherwise indicated). The Company's quarterly report on Form 10-Q, which includes unaudited consolidated financial statements and management's discussion and analysis ("MD&A") for the quarter ended September 30, 2026, is being filed and made accessible under the Company's continuous disclosure profile on SEDAR+ at www.sedarplus.ca and will also be available on EDGAR at www.sec.gov/edgar. Third Quarter 2026 Highlights All amounts in U.S. dollars (millions) Revenue of $12.25 million, up 85% from the previously completed fiscal quarter and an increase of 50% compared to the quarter ended September 30, 2025; $119.6 million in cash, cash equivalents and digital currencies, $103.0 mill

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye